Drugs / Cvac
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01521143 | Jan 2012 → Mar 2015 | malignant epithelial tumor of ovary | Prima BioMed Ltd | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cvac | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01521143 ↗ |
| Modality | Cell therapy | “The purpose of this study is to determine if an investigational cell therapy called Cvac can help epithelial ovarian cancer (EOC) from returning” NCT01521143 ↗ |